Exosomes derived from first-trimester human decidual mesenchymal stem cell - PubMed
a day ago
- #premature ovarian insufficiency
- #exosomes
- #mesenchymal stem cells
- Exosomes from first-trimester human decidual mesenchymal stem cells (FthDMSC-EXOs) have advantages over parental MSCs, like higher yield and better bioimmunological safety.
- FthDMSCs were isolated from decidual tissue at 7-11 gestational weeks and showed positive markers (CD105, CD73, CD90) and tri-lineage differentiation capacity.
- FthDMSC-EXOs were characterized with markers CD9 and TSG101, bilayer membrane morphology, and a particle size around 150 nm.
- In vivo, FthDMSC-EXOs significantly improved ovarian function in a mouse model of premature ovarian insufficiency (POI) induced by cyclophosphamide.
- The study provides a new method for obtaining high-quality MSC-derived exosomes, supporting further research into gynecological disease therapies.